Navigation Links
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Date:6/23/2009

than 3,500 patients reported as having been treated with nimotuzumab worldwide to date, no Grade IV incidents of radiation dermatitis have been described, severe rash has not been observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been rare. Nimotuzumab is licensed to YM's majority-owned subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using fentanyl because patients can individually control the analgesia required for their differing intensities of pain. AeroLEF met all endpoints in a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 17, 2013 Z Trim Holdings, Inc. ... providing value-added ingredients to a variety of industries, ... new meat application at this year,s annual Institute ... Chicago , July 13-16. The Company will ... expensive/chemically-modified ingredients in meat products thereby helping manufacturers ...
(Date:6/17/2013)... Yongye International, Inc. (NASDAQ:   YONG) ("Yongye" or the ... nutrient products in the People,s Republic of ... stock will resume trading on the NASDAQ Stock Market ... Time. As previously disclosed, NASDAQ halted trading ... following Yongye,s notification that the filing of its Annual ...
(Date:6/16/2013)... This training is ideal for those who ... the software industry or those who want to explore Agile ... , The topics that will be covered in the 1-day ... meetings, scrum artifacts, and scrum simulation (optional). , The ... CO June 28, 2013 , Click here to register for ...
(Date:6/14/2013)... June 14, 2013 Case Western ... SPR™ Therapeutics, and Valtronic, has been awarded a ... Commission to commercialize a neurostimulation technology platform designed ... needs, including pain and muscle paralysis. ... connects Ohio companies with the technology development and ...
Breaking Biology Technology:Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013 2Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013 3Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013 4Affordable Scrum Trainings in Denver, CO – 8 PDUs (June 28, 2013) by Conscires Agile Practices 2Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 2Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 3Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 4
... , ... wastes has never been easier, or less smelly, thanks to a new indoor composting ... composting bucket collects food scraps in an airtight bucket. Bokashi, made using SCD,s probiotic ... , ...
... May 18 Caliper Life Sciences, Inc. (Nasdaq: CALP ... life sciences research, today announced that it reached an agreement to sell ... product lines to Biotage AB for $16.5 million in cash. ... "Divesting these product ...
... May 17 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" ... for the first quarter ended March 31, 2010 . , ... Results for the Quarter Ended March 31, 2010 , ... The Company recorded $49.06 million of revenues for ...
Cached Biology Technology:All Seasons Indoor Composter™ and All Seasons Bokashi™ Provide Easy Way to Recycle Food Waste Right in Your Kitchen 2All Seasons Indoor Composter™ and All Seasons Bokashi™ Provide Easy Way to Recycle Food Waste Right in Your Kitchen 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 2Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 4Dragon Pharma reports 2010 first quarter financial results 2Dragon Pharma reports 2010 first quarter financial results 3Dragon Pharma reports 2010 first quarter financial results 4Dragon Pharma reports 2010 first quarter financial results 5
(Date:6/14/2013)... the journal Science , Swedish and Australian researchers ... old fossil fishes, revealed by unique fossils from a ... to understand how neck muscles and abdominal muscles ... up a vision of rattling skeletons. Bones and teeth ... usually the only traces of the animal that remain. ...
(Date:6/13/2013)... The World Cultural Council is proud to announce that ... presentations, with its 30th Award Ceremony on Wednesday, 2nd ... and the Programme will be available shortly. , ... criteria for the Science Award of bringing "true benefit ... a scientific leader of several prestigious organizations, with significant ...
(Date:6/13/2013)... MEDFORD/SOMERVILLE, Mass. - Qiaobing Xu, assistant professor of ... was named a Pew Scholar in Biomedical Sciences ... highly competitive program, whose past winners have included ... the Albert Lasker Basic Medical Research Award, identifies ... work focuses on nanotechnology for biomedical uses. He ...
Breaking Biology News(10 mins):2013 World Cultural Council awards 22013 World Cultural Council awards 3Tufts Engineer Qiaobing Xu named 2013 Pew Scholar 2
... Sciences has elected James Birchler, Curators, Professor of Biological ... as a member. Birchler will be inducted into the ... D.C. The National Academy of Sciences is a ... scientific and engineering research, dedicated to furthering science and ...
... (BRONX, NY) There are no effective treatments for rhabdoid tumors ... old and affect the brain or kidneys. The disease is extremely ... the U.S. but is particularly difficult to treat and almost ... of Medicine of Yeshiva University have identified a target for ...
... certain strains of Aspergillus fungi appear to be ... say scientists. University of Manchester researchers, working with colleagues ... not only better diagnose Aspergillus infection, but can ... class of drugs used to treat patients with aspergillosis. ...
Cached Biology News:MU professor elected to membership in National Academy of Sciences 2MU professor elected to membership in National Academy of Sciences 3Einstein researchers find key gene in childhood cancer 2Drug-resistance fears for deadly fungal disease 2
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... High Five cells (BTI-TN-5B1-4) derived ... have been shown to be capable ... secreted recombinant proteins compared to other ... the following features:- -Rapid doubling time as ...
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
Biology Products: